Maria E Trujillo

Dr. Maria E Trujillo


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2017 in Science
Verified
Journal Article
Closed access
PDF file
RMRobert W. Myers
Robert W. Myers
HGHong-Ping Guan
Hong-Ping Guan
JEJuliann Ehrhart
Juliann Ehrhart
APAleksandr Petrov
Aleksandr Petrov
SPSrinivasa Prahalada
Srinivasa Prahalada
ISIyassu K. Sebhat
Iyassu K. Sebhat
Hitting a dozen enzymes with one drug: The adenosine monophosphate-activated protein kinase (AMPK) controls cellular energy status. AMPK is activated when energy levels fall. This stimulates adenosine triphosphate (ATP)-generating pathways that promote glucose uptake and inhibits ATP-consuming pathways associated with glucose synthesis. In principle, these effects would be beneficial in metabolic diseases, including diabetes. Pharmacological activation of AMPK has been challenging, however, because in mammals, the enzyme exists as 12 distinct complexes. Myers et al. describe an orally available compound (MK-8722) that activates all 12 complexes (see the Perspective by Hardie). In animal models, MK-8722 ameliorated diabetes, but it also caused enlargement of the heart. MK-8722 may be a useful tool compound for laboratory research on AMPK function. Science , this issue p. 507 ; see also p. 455

23 November 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
MTMaria E Trujillo
Maria E Trujillo
SASurya Ayalasomayajula
Surya Ayalasomayajula
RBRobert O. Blaustein
Robert O. Blaustein
FGFerdous Gheyas
Ferdous Gheyas
Vericiguat, a novel soluble guanylate cyclase (sGC) stimulator, is approved for the treatment of heart failure (HF) with reduced ejection fraction (HFrEF). Decreased nitric oxide (NO) availability, sGC desensitization to NO, sGC deficiency, and reduced cyclic guanosine monophosphate (cGMP) signaling are potential contributing factors for HF disease progression. Vericiguat works via stimulation of sGC in the critical NO‐sGC‐cGMP pathway. Vericiguat is primarily metabolized by glucuronidation via uridine diphosphate‐glucuronosyltransferase (UGT) isoforms UGT1A1 and UGT1A9. Urinary excretion and renal clearance of vericiguat are low. No intrinsic factor had a clinically relevant effect on vericiguat exposure. Vericiguat has low drug–drug interaction potential with no clinically relevant pharmacokinetic or pharmacodynamic interactions observed with warfarin, digoxin, aspirin, or sacubitril/valsartan. The global phase III study VICTORIA included patients with HFrEF who had a recent HF hospitalization or intravenous diuretic treatment for HF. Treatment with vericiguat on top of standard of care resulted in a 10% relative reduction in the primary composite outcome of death from cardiovascular causes or first hospitalization for HF. Vericiguat was well‐tolerated with low incidence of symptomatic hypotension and syncope compared to placebo. Given its positive benefit–risk profile, vericiguat is an important option for high‐risk patients with HFrEF who are already on guideline‐directed medical therapy and had recent worsening of HF. Future efforts to develop additional effective therapies are needed to further reduce morbidity and mortality in patients with HF.

1 July 2017 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
JGJudith N. Gorski
Judith N. Gorski
MPMichele J. Pachanski
Michele J. Pachanski
JMJoel Mane
Joel Mane
CPChristopher W. Plummer
Christopher W. Plummer
SSSarah Souza
Sarah Souza
MTMaria E Trujillo
Maria E Trujillo
G protein-coupled receptor 40 (GPR40) partial agonists lower glucose through the potentiation of glucose-stimulated insulin secretion, which is believed to provide significant glucose lowering without the weight gain or hypoglycemic risk associated with exogenous insulin or glucose-independent insulin secretagogues. The class of small-molecule GPR40 modulators, known as AgoPAMs (agonist also capable of acting as positive allosteric modulators), differentiate from partial agonists, binding to a distinct site and functioning as full agonists to stimulate the secretion of both insulin and glucagon-like peptide-1 (GLP-1). Here we show that GPR40 AgoPAMs significantly increase active GLP-1 levels and reduce acute and chronic food intake and body weight in diet-induced obese (DIO) mice. These effects of AgoPAM treatment on food intake are novel and required both GPR40 and GLP-1 receptor signaling pathways, as demonstrated in GPR40 and GLP-1 receptor-null mice. Furthermore, weight loss associated with GPR40 AgoPAMs was accompanied by a significant reduction in gastric motility in these DIO mice. Chronic treatment with a GPR40 AgoPAM, in combination with a dipeptidyl peptidase IV inhibitor, synergistically decreased food intake and body weight in the mouse. The effect of GPR40 AgoPAMs on GLP-1 secretion was recapitulated in lean, healthy rhesus macaque demonstrating that the putative mechanism mediating weight loss translates to higher species. Together, our data indicate effects of AgoPAMs that go beyond glucose lowering previously observed with GPR40 partial agonist treatment with additional potential for weight loss.

20 October 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMichele J. Pachanski
Michele J. Pachanski
MKMelissa E. Kirkland
Melissa E. Kirkland
DKDaniel T. Kosinski
Daniel T. Kosinski
JMJoel Mane
Joel Mane
BCBoonlert Cheewatrakoolpong
Boonlert Cheewatrakoolpong
MTMaria E Trujillo
Maria E Trujillo
GPR40 agonists are effective antidiabetic agents believed to lower glucose through direct effects on the beta cell to increase glucose stimulated insulin secretion. However, not all GPR40 agonists are the same. Partial agonists lower glucose through direct effects on the pancreas, whereas GPR40 AgoPAMs may incorporate additional therapeutic effects through increases in insulinotrophic incretins secreted by the gut. Here we describe how GPR40 AgoPAMs stimulate both insulin and incretin secretion in vivo over time in diabetic GK rats. We also describe effects of AgoPAMs in vivo to lower glucose and body weight beyond what is seen with partial GPR40 agonists in both the acute and chronic setting. Further comparisons of the glucose lowering profile of AgoPAMs suggest these compounds may possess greater glucose control even in the presence of elevated glucagon secretion, an unexpected feature observed with both acute and chronic treatment with AgoPAMs. Together these studies highlight the complexity of GPR40 pharmacology and the potential additional benefits AgoPAMs may possess above partial agonists for the diabetic patient.

13 August 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MTMaria E Trujillo
Maria E Trujillo
LALeticia Arrington
Leticia Arrington
YPYogesh Patel
Yogesh Patel
JPJulie Passarell
Julie Passarell
LWLarissa Wenning
Larissa Wenning
FGFerdous Gheyas
Ferdous Gheyas

23 May 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CMCorin Miller
Corin Miller
MPMichele J. Pachanski
Michele J. Pachanski
MKMelissa E. Kirkland
Melissa E. Kirkland
DKDaniel T. Kosinski
Daniel T. Kosinski
JMJoel Mane
Joel Mane
MTMaria E Trujillo
Maria E Trujillo
GPR40 (FFA1) is a fatty acid receptor whose activation results in potent glucose lowering and insulinotropic effects in vivo. Several reports illustrate that GPR40 agonists exert glucose lowering in diabetic humans. To assess the mechanisms by which GPR40 partial agonists improve glucose homeostasis, we evaluated the effects of MK-2305, a potent and selective partial GPR40 agonist, in diabetic Goto Kakizaki rats. MK-2305 decreased fasting glucose after acute and chronic treatment. MK-2305-mediated changes in glucose were coupled with increases in plasma insulin during hyperglycemia and glucose challenges but not during fasting, when glucose was normalized. To determine the mechanism(s) mediating these changes in glucose metabolism, we measured the absolute contribution of precursors to glucose production in the presence or absence of MK-2305. MK-2305 treatment resulted in decreased endogenous glucose production (EGP) driven primarily through changes in gluconeogenesis from substrates entering at the TCA cycle. The decrease in EGP was not likely due to a direct effect on the liver, as isolated perfused liver studies showed no effect of MK-2305 ex vivo and GPR40 is not expressed in the liver. Taken together, our results suggest MK-2305 treatment increases glucose stimulated insulin secretion (GSIS), resulting in changes to hepatic substrate handling that improve glucose homeostasis in the diabetic state. Importantly, these data extend our understanding of the underlying mechanisms by which GPR40 partial agonists reduce hyperglycemia.